Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The potential for over-restriction and inadequate nutrition increases
One small study found that about 80 percent of patients said their periods became more regular
Consult a weight loss physician to transition GLP-1 medications to avoid potential side effects that come up during dosage changes
Peptide Sciences shut down in March 2026 after generating $7.4 million per month
That does not mean failure
Retatrutide, a novel GLP-1 drug in Phase 3, has not yet been approved by the FDA, restricting access to clinical environments and ruling out regular prescriptions in most locations
US$ 20.86
US$ 25.30
US$ 23.37
US$ 27.35
US$ 27.35
